The treatment paradigm of early TNBC has had a real evolution since July 2021, with the introduction of immunotherapy following the Food and Drug Administration (FDA) approval of pembrolizumab for high-risk TNBC (tumor size > 1 cm but ≤ 2 cm in diameter with nodal involvement or tumor size > 2 cm in diameter regardless of nodal involvement), regardless of tumor PD-L1 expression, in combination with CHT as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery for a total duration of approximately 1 year [83]. Here, CD274 is linked to neoplasm.